CDKN2A and cancer: To determine the association between CDKN2A ALT and response to ICIs among pan-cancer patients treated with immunotherapy (CTLA-4 blockade, PD-1/PD-L1 blockade or combination), tumor-specific ORRs were summarized according to some cancer immunotherapy studies.